Ascendis Pharma A/S
ASND
Rank in Stocks
#1547
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Share Price
$224.87
Last synced: 2026-10-16
Market Cap
$14.03B
Change (1 day)
-0.77%
Change (1 year)
6.83%
Country
DK
Trade Ascendis Pharma A/S (ASND)
Category
Healthcare
EPS for Ascendis Pharma A/S (ASND)
EPS as of June 2026 TTM: $14.35
According to Ascendis Pharma A/S latest financial reports and stock price the company's current EPS (TTM) is $14.35. At the end of 2024 the company had a EPS of $-6.79 a decrease compared to its 2023 EPS that were of $-9.45.
EPS history for Ascendis Pharma A/S from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $14.35 | -437.71% |
| 2025 | $-4.25 | -37.49% |
| 2024 | $-6.79 | -28.11% |
| 2023 | $-9.45 | -15.28% |
| 2022 | $-11.16 | 40.15% |
| 2021 | $-7.96 | -21.06% |
| 2020 | $-10.08 | 91.63% |
| 2019 | $-5.26 | 44.45% |
| 2018 | $-3.64 | -17.50% |
| 2017 | $-4.42 | 62.66% |
| 2016 | $-2.71 | 79.86% |
| 2015 | $-1.51 | 118.83% |
| 2014 | $-0.69 | -231.97% |
| 2013 | $0.52 | 230.13% |
| 2012 | $0.16 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | 20.68% |
US
|
|
| $-7.98 | -155.60% |
US
|
|
| $-5.29 | -136.86% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 93.28% |
NL
|
